ArticleArchives of medical science : AMS2025
METTL3-mediated miR-4534 maturation promotes IVDD progression by targeting the Sirt6-mediated Nrf2/HO-1 pathway.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Superoxide dismutase in intervertebral disc degeneration: from pathophysiological mechanism to therapeutic strategies.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intervertebral disc degeneration (IVDD) is a significant contributor to the development of discogenic low back pain and impairment. Apoptosis and degradation of the extracellular matrix (ECM) have also been reported to be major factors in IVDD. However, current treatments are unable to cure it, and the exact mechanisms are not fully understood. Material and methods: Nucleus pulposus (NP) tissues were collected from individuals diagnosed with either IVDD or lumbar vertebral fractures, whereas nucleus pulposus cells (NPCs) were isolated from non-degenerative, healthy NP tissues. The IVDD cell model was established by treating NPCs with IL-β at a concentration of 20 ng/ml, and an animal model was induced through annulus fibrosus puncture surgery. Histological examination of NP tissues was performed using HE staining. Analysis of mRNA and protein expression was performed using qRT-PCR and western blot techniques. Cellular viability was assessed using the CCK-8 assay, flow cytometry and TUNEL assays were employed to evaluate cellular apoptosis, the binding interaction between miR-4534 and Sirt6 was confirmed via a dual-luciferase reporter system, and we utilized RIP and Me-RIP methods to provide evidence of m6A modification in pri-miR-4534. Results: MiR-4534 was found to be upregulated in NP tissues affected by IVDD, and it promoted apoptosis of NPCs and ECM degradation by inhibiting Sirt6 expression and inactivating the Nrf2/HO-1 pathway. Furthermore, this upregulation was attributed to m6A epigenetic modification of pri-miR-4534, facilitated by METTL3, and the knockdown of METTL3 alleviated the progression of IVDD. Conclusions: MiR-4534, upregulated through METTL3-mediated m6A modification, functions by suppressing Sirt6 and deactivating the Nrf2/HO-1 pathway, which, in turn, promotes apoptosis of NPCs and contributes to ECM degradation, thereby facilitating the progression of IVDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.